Dxd（ADC 的 Exatecan 衍生物）是一种有效的 DNA 拓扑异构酶 I 抑制剂，IC 50 为 0.31 μM，用作 HER2 靶向 ADC（DS-8201a）的结合药物。 Dxd 对人类癌细胞系 KPL-4、NCI-N87、SK …

Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC 50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). Dxd is cytotoxic to …

2022年9月9日 · T-DXd作为概念验证的研究建立了一种新的ADC连接子有效载荷系统，通过使用独特的TOP1抑制剂DXd和稳定的连接子，显示了卓效的疗效和可接受的安全性。 T-DXd可谓是 …

2023年9月27日 · t-dxd是新一代adc药物的突出代表，其载药dxd属于cpt的水溶性非前体药物类似物，cpt衍生物含有a、b、c、d、e五个环。ab为喹啉环，c为吡咯环，d为吡啶环，e为α-羟基 …

The novel exatecan derivative, DXd, is 10 times more potent than the active form of irinotecan, SN-38, in inhibiting topoisomerase I. DXd was used in several proprietary ADC programs, …

2024年10月1日 · DS-7300a is an ADC drug targeting B7-H3 synthesized using DXd-ADC technology by linking a humanized monoclonal antibody targeting B7-H3 with a novel …

DXd is a topoisomerase I inhibitor that induces DNA damage leading to cell cycle arrest, making it an option for ADC payloads. The DXd-ADC technology, developed by Daiichi Sankyo, is a …

Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7-8 with the topoisomerase I inhibitor DXd. In …

2024年4月15日 · Dato-DXd is a TROP-2 directed ADC consisting of a humanized anti-TROP-2 IgG1 monoclonal antibody (Mab) linked to a topoisomerase I inhibitor payload by tetrapeptide …

Trastuzumab deruxtecan is a humanized anti-HER2 IgG1 antibody, targeting cancer cause by mutation of the HER2 gene. In addition, the small molecule portion of this drug, deruxtecan …